RNA interference-mediated silencing of NANOG leads to reduced proliferation and self-renewal, cell cycle arrest and apoptosis in T-cell acute lymphoblastic leukemia cells via the p53 signaling pathway

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1170-1177

  Cao, Jiang ^a,b   Li, Li ^b   Chen, Chong ^b   Lv, Chao ^b   Meng, Fanjing ^b   Zeng, Lingyu ^b   Li, Zhenyu ^b   Wu, Qingyun ^b   Zhao, Kai ^b   Pan, Bin ^b   Cheng, Hai ^b   Chen, Wei ^b   Xu, Kailin ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

NANOG; P53; T cell acute lymphoblastic leukemia

Indexed keywords

MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR NANOG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NANOG GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SEQUENCE; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA;

NANOG; P53; T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880927484     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.021     Document Type: Article

References (51)

1. Hannon M.M., Lohan F., Erbilgin Y., Sayitoglu M., O'Hagan K., Mills K., et al. Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL. Br J Haematol 2012, 158:626-634.
2. Simioni C., Neri L.M., Tabellini G., Ricci F., Bressanin D., Chiarini F., et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26:2336-2342.
3. De Keersmaecker K., Marynen P., Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005, 90:1116-1127.
4. Schoenhals M., Kassambara A., De Vos J., Hose D., Moreaux J., Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009, 383:157-162.
5. Blackburn J.S., Liu S., Raiser D.M., Martinez S.A., Feng H., Meeker N.D., et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012, 26:2069-2078.
6. Ma W., Gutierrez A., Goff D.J., Geron I., Sadarangani A., Jamieson C.A., et al. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS ONE 2012, 7:e39725.
7. Mirandola L., Comi P., Cobos E., Kast W.M., Chiriva-Internati M., Chiaramonte R. Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett 2011, 308:1-13.
8. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
9. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
10. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
11. McCormack M.P., Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350:913-922.
12. McCormack M.P., Young L.F., Vasudevan S., de Graaf C.A., Codrington R., Rabbitts T.H., et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 2010, 327:879-883.
13. Chia N.Y., Chan Y.S., Feng B., Lu X., Orlov Y.L., Moreau D., et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 2010, 468:316-320.
14. Dettman E.J., Simko S.J., Ayanga B., Carofino B.L., Margolin J.F., Morse H.C., et al. Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene 2011, 30:2859-2873.
15. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
16. Li Y.Q. Master stem cell transcription factors and signaling regulation. Cell Reprogram 2010, 12:3-13.
17. Wang Z., Oron E., Nelson B., Razis S., Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 2012, 10:440-454.
18. Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., et al. The homeoprotein NANOG is required for maintenance of pluripotency in mouse Epiblast and ES cells. Cell 2003, 113:631-642.
19. Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S., et al. Functional expression cloning of NANOG, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655.
20. Hart A.H., Hartley L., Parker K., Ibrahim M., Looijenga L.H.J., Pauchnik M., et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005, 104:2092-2098.
21. Hoei-Hansen C.E., Sehested A., Juhler M., Lau Y.F., Skakkebaek N.E., Laursen H., et al. New evidence for the origin of intracranial germ cell tumours from primordial germ cells: expression of pluripotency and cell differentiation markers. J Pathol 2006, 209:25-33.
22. You J.S., Kang J.K., Seo D.W., Park J.H., Park J.W., Lee J.C., et al. Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of NANOG suppression. Cancer Res 2009, 69:5716-5725.
23. Jeter C.R., Badeaux M., Choy G., Chandra D., Patrawala L., Liu C., et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009, 27:993-1005.
24. Gu G., Yuan J., Wills M., Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007, 67:4807-4815.
25. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
26. Zbinden M., Duquet A., Lorente-Trigos S.-N., Ngwabyt I., Borges A., Altaba R.I. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010, 29:2659-2674.
27. Ye F., Zhou C., Cheng Q., Shen J., Chen H. Stem-cell-abundant proteins NANOG, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008, 8:108.
28. Jeter C.R., Liu B., Liu X., Chen X., Liu C., Calhoun-Davis T., et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011, 30:3833-3845.
29. Chen L.S., Redkar S., Taverna P., Cortes J.E., Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011, 118:693-702.
30. Booth H.A., Holland P.W. Eleven daughters of NANOG. Genomics 2004, 84:229-238.
31. Ambady S., Malcuit C., Kashpur O., Kole D., Holmes W.F., Hedblom E., et al. Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol 2010, 54:1743-1754.
32. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000, 910:121-137. discussion 137-129.
33. Wang X., Jiang X. Mdm2 and MdmX partner to regulate p53. FEBS Lett 2012, 586:1390-1396.
34. Shapiro G.I., Edwards C.D., Rollins B.J. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys 2000, 33:189-197.
35. Oliva J., French B.A., Qing X., French S.W. The identification of stem cells in human liver diseases and hepatocellular carcinoma. Exp Mol Pathol 2010, 88:331-340.
36. Lee T.K.W., Castilho A., Cheung V.C.H., Tang K.H., Ma S., Ng I.O.L. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9:50-63.
37. Ma L., Lai D., Liu T., Cheng W., Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochimica et Biophysica Sinica 2010, 42:593-602.
38. Seigel G.M., Hackam A.S., Ganguly A., Mandell L.M., Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007, 13:823-832.
39. Nirasawa S., Kobayashi D., Tsuji N., Kuribayashi K., Watanabe N. Diagnostic relevance of overexpressed NANOG gene in early lung cancers. Oncol Rep 2009, 22:587-591.
40. Meng H.M., Zheng P., Wang X.Y., Liu C., Sui H.M., Wu S.J., et al. Overexpression of NANOG predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010, 9:295-302.
41. Piestun D., Kochupurakkal B.S., Jacob-Hirsch J., Zeligson S., Koudritsky M., Domany E., et al. NANOG transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun 2006, 343:279-285.
42. Zhang X., Neganova I., Przyborski S., Yang C., Cooke M., Atkinson S.P., et al. A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A. J Cell Biol 2009, 184:67-82.
43. Han J., Zhang F., Yu M., Zhao P., Ji W., Zhang H., et al. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012, 321:80-88.
44. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., et al. p53 induces differentiation of mouse embryonic stem cells by suppressing NANOG expression. Nat Cell Biol 2005, 7:165-171.
45. Qin H., Yu T., Qing T., Liu Y., Zhao Y., Cai J., et al. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J Biol Chem 2007, 282:5842-5852.
46. Maimets T., Neganova I., Armstrong L., Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 2008, 27:5277-5287.
47. Ungewitter E., Scrable H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 2010, 24:2408-2419.
48. Chen T., Du J., Lu G. Cell growth arrest and apoptosis induced by Oct4 or NANOG knockdown in mouse embryonic stem cells: a possible role of Trp53. Mol Biol Rep 2012, 39:1855-1861.
49. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414.
50. Stead E., White J., Faast R., Conn S., Goldstone S., Rathjen J., et al. Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene 2002, 21:8320-8333.
51. Moldovan G.L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell 2007, 129:665-679.